PDF下载 ( 223 KB)
Drug resistance of direct-acting antivirals in genotype 2/3 hepatitis C virus
-
摘要:
自针对HCV的直接抗病毒药物问世以来,超过95%的丙型肝炎患者可以获得治愈,但仍有极小部分患者面临治疗失败的情况。造成治疗失败的原因有很多,而HCV基因型以及病毒基因中的耐药相关替代（RAS）在其中有着一定的影响。介绍了目前对HCV基因2、3型的病毒株中,NS5B、NS5A基因片段相关的RAS位点,总结了其分布的情况以及在慢性丙型肝炎直接抗病毒药物初治患者与治疗失败患者之间RAS分布的差异。
Abstract:Since the development of direct-acting antivirals( DAAs) for hepatitis C virus( HCV),more than 95% of the patients with hepatitis C can be cured,but a very small proportion of patients still face treatment failure. There are many reasons for treatment failure,among which HCV genotype and resistance-associated substitutions( RASs) in virus genes show a certain impact. This article mainly introduces the RASs associated with the NS5 B and NS5 A gene fragments in genotype 2/3 HCV,summarizes the distribution of RASs,and compares the difference in the distribution of RASs between previously untreated chronic hepatitis C patients and patients with treatment failure.
-
Key words:
- hepacivirus /
- antiviral agents /
- therapeutics
-
[1] Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. The guideline of prevention and treatment for hepatitis C(2019 version)[J]. J Clin Hepatol,2019,35(12):2670-2686.(in Chinese)中华医学会肝病学分会，中华医学会感染病学分会．丙型肝炎防治指南(2019年版)[J]．临床肝胆病杂志，2019,35(12):2670-2686. [2] di MAIO VC,CENTO V,ARAGRI M,et al. Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures:What are the chances for second-line regimens?[J]. J Hepatol,2018,68(3):597-600. [3] SARRAZIN C,DVORY-SOBOL H,SVAROVSKAIA ES,et al.Prevalence of resistance-associated substitutions in HCV NS5A,NS5B,or NS3 and outcomes of treatment with ledipasvir and sofosbuvir[J]. Gastroenterology,2016,151(3):501-512. e1. [4] PAWLOTSKY JM. Hepatitis C drugs:Is next generation the last generation?[J]. Gastroenterology,2016,151(4):587-590. [5] BAUMERT TF,BERG T,LIM JK,et al. Status of direct-acting antiviral therapy for hepatitis C virus infection and remaining challenges[J]. Gastroenterology,2019,156(2):431-445. [6] RAO HY,Directly acting antiviral agents in hepatitis C[J]. J Prac Hepatol,2016,19(4):390-393.(in Chinese)饶慧瑛．丙型肝炎直接抗病毒治疗研究进展[J]．实用肝脏病杂志，2016,19(4):390-393. [7] SARRAZIN C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice[J]. J Hepatol,2016,64(2):486-504. [8] PAWLOTSKY JM. Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens[J]. Gastroenterology,2016,151(1):70-86. [9] ZHANG Y,CAO Y,ZHANG RW,et al. Natural resistance mutations to direct-acting antiviral agents in interferon/ribavirin treatment-experienced and treatment-naive patients with chronic hepatitis C in Beijing,China[J]. J Clin Hepatol,2016,32(4):711-715.(in Chinese)张玉，曹颖，张仁雯，等．北京地区干扰素联合利巴韦林经治与未经治慢性丙型肝炎患者直接抗病毒药物的天然耐药突变分析[J]．临床肝胆病杂志，2016,32(4):711-715. [10] CHEN Q,PERALES C,SORIA ME,et al. Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure[J]. Antiviral Res,2020,174:104694. [11] CHEN JH,XU XY. Research of HCV variants resistant to direct-acting antiviral agents[J]. Infect Dis Info,2016,29(2):116-120.(in Chinese)陈建宏，徐小元．丙型肝炎直接抗病毒药物耐药相关变异的研究[J]．传染病信息，2016,29(2):116-120. [12] PARLATI L,POL S. Direct acting antivirals failure:Cause and retreatment options[J]. Expert Rev Gastroenterol Hepatol,2018,12(12):1245-1250. [13] CECCHERINI-SILBERSTEIN F,CENTO V,di MAIO VC,et al. Viral resistance in HCV infection[J]. Curr Opin Virol,2018,32:115-127. [14] di MAIO VC,CENTO V,LENCI I,et al. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies[J]. Liver Int,2017,37(4):514-528. [15] LONTOK E,HARRINGTON P,HOWE A,et al. Hepatitis C virus drug resistance-associated substitutions:State of the art summary[J]. Hepatology,2015,62(5):1623-1632. [16] WU R,GENG D,CHI X,et al. Computational analysis of naturally occurring resistance-associated substitutions in genes NS3,NS5A,and NS5B among 86 subtypes of hepatitis C virus worldwide[J]. Infect Drug Resist,2019,12:2987-3015. [17] HAN B,MARTIN R,XU S,et al. Sofosbuvir susceptibility of genotype 1 to 6 HCV from DAA-na6ve subjects[J]. Antiviral Res,2019,170:104574. [18] DIETZ J,SUSSER S,VERMEHREN J,et al. Patterns of resistance-associated substitutions in patients with chronic HCV infection following treatment with direct-acting antivirals[J].Gastroenterology,2018,154(4):976-988. e4. [19] LIU Z,MAO X,YU K,et al. Prevalence of HCV resistanceassociated substitutions amongtreatment failurepatients receiving direct-acting antiviral agents[J]. J Viral Hepat,2020,27(6):585-592. [20] LIU Z,MAO X,WU J,et al. World-wide prevalence of substitutions in HCV genome associated with resistance to directacting antiviral agents[J]. Clin Gastroenterol Hepatol,2019. [21] WING P,JONES M,CHEUNG M,et al. Amino acid substitutions in genotype 3a hepatitis C virus polymerase protein affect responses to sofosbuvir[J]. Gastroenterology,2019,157(3):692-704. e9. [22] HARRINGTON PR,KOMATSU TE,DEMING DJ,et al. Impact of hepatitis C virus polymorphisms on direct-acting antiviral treatment efficacy:Regulatory analyses and perspectives[J].Hepatology,2018,67(6):2430-2448. [23] PEREZ AB,CHUECA N,GARCIA-DELTORO M,et al. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world[J]. J Hepatol,2019,71(5):876-888. [24] LAWITZ EJ,DVORY-SOBOL H,DOEHLE BP,et al. Clinical resistance to velpatasvir(GS-5816),a novel pan-genotypic inhibitor of the hepatitis C virus NS5A protein[J]. Antimicrob Agents Chemother,2016,60(9):5368-5378. [25] DVORY-SOBOL H,HAN B,LU J,et al. In vitro resistance profile of hepatitis C virus NS5A inhibitor velpatasvir in genotypes 1 to 6[J]. J Viral Hepat,2019,26(8):991-1001. [26] ESTEBAN R,PINEDA JA,CALLEJA JL,et al. Efficacy of sofosbuvir and velpatasvir,with and without ribavirin,in patients with hepatitis C virus genotype 3 infection and cirrhosis[J].Gastroenterology,2018,155(4):1120-1127. e4. [27] MCPHEE F. Developments in the treatment of HCV genotype 3 infection[J]. Expert Rev Anti Infect Ther,2019,17(10):775-785. [28] SEZAKI H,SUZUKI F,HOSAKA T,et al. Initial-and retreatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3infections[J]. J Gastroenterol,2019,54(10):916-927. [29] DIETZ J,SPENGLER U,MULLHAUPT B,et al. Efficacy of retreatment after failed direct-acting antiviral therapy in patients with HCV genotype 1-3 infections[J]. Clin Gastroenterol Hepatol,2019. [30] OSAWA M,IMAMURA M,TERAOKA Y,et al. Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures[J]. J Gastroenterol,2019,54(3):291-296. [31] GOTTWEIN JM,PHAM LV,MIKKELSEN LS,et al. Efficacy of NS5A inhibitors against hepatitis C virus genotypes 1-7and escape variants[J]. Gastroenterology,2018,154(5):1435-1448. [32] KRISHNAN P,SCHNELL G,TRIPATHI R,et al. Integrated resistance analysis of CERTAIN-1 and CERTAIN-2 studies in hepatitis C virus-infected patients receiving glecaprevir and pibrentasvir in Japan[J]. Antimicrob Agents Chemother,2018,62(2). [33] SORBO MC,CENTOV,DI MAIO VC,et al. Hepatitis C virus drug resistance associated substitutions and their clinical relevance:Update 2018[J]. Drug Resist Updat,2018,37. [34] CHEN JH,ZENG Z,ZHANG XX,et al. Efficacy and safety of combined directly acting antivirals for treatment of Chinese chronic hepatitis C patients in a real-world setting[J]. World J Gastroenterol,2017,23(22):4072-4079. [35] BUTI M,ESTEBAN R. Management of direct antiviral agent failures[J]. Clin Mol Hepatol,2016,22(4):432-8. -
本文二维码
计量
- 文章访问数: 541
- HTML全文浏览量: 18
- PDF下载量: 82
- 被引次数: 0
下载:
